Molecular analysis of glioblastoma cell lines, patient-derived cell cultures and clinical samples from phase I clinical trials suggest that the expression of promyelocytic leukemia (PML) gene may be responsible for resistance to cytotoxicity of mTOR inhibition (115). This evidence concerns the gene MTOR and glioblastoma.